Changes in antibiotic resistance level of nosocomial Pseudomonas aeruginosa isolates in the largest university hospital of Lithuania.

UNLABELLED The aim was to estimate changes in the resistance rates of Pseudomonas aeruginosa (P. aeruginosa) strains isolated from patients treated in intensive care units of the largest university hospital. MATERIALS AND METHODS Isolates were identified with the Phoenix ID system (Becton Dickinson, USA). The minimum inhibitory concentration (MIC) of ceftazidime, ciprofloxacin, and amikacin were determined by the E-test and evaluated following the recommendations of the Clinical Laboratory Standards Institute. RESULTS In 2003, the proportion of P. aeruginosa strains resistant to piperacillin was greatest followed by strains resistant gentamicin and ciprofloxacin. In 2008, the resistance rates markedly changed being the highest to ciprofloxacin. An increase in the resistance rates to ciprofloxacin (+24%, P<0.001) and ceftazidime (+8.3%, P<0.05) was documented. In 2003, there were 66.7% of P. aeruginosa strains sensitive to all antibiotics tested, and this percentage decreased to 47.5% in 2008 (P<0.05). During the study, a significant increase in the median MICs for ciprofloxacin and amikacin was observed (P<0.001); however, no significant change was documented for ceftazidime. CONCLUSIONS P. aeruginosa remains an important nosocomial pathogen with relatively high overall resistance to antimicrobial agents, and the resistance level is increasing.

[1]  V. di Pilato,et al.  Pseudomonas aeruginosa infection in cystic fibrosis caused by an epidemic metallo-β-lactamase-producing clone with a heterogeneous carbapenem resistance phenotype. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  A. Torres,et al.  Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  J. Lavigne,et al.  Évolution de la résistance aux antibiotiques de Pseudomonas aeruginosa dans un centre hospitalier universitaire entre 2002 et 2006 , 2010 .

[4]  R. Sakalauskas,et al.  Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality. , 2010, Medicina.

[5]  L. Molinari,et al.  [Evolution of antimicrobial resistance against Pseudomonas aeruginosa in a French university hospital between 2002 and 2006]. , 2010, Pathologie-biologie.

[6]  A. Vitkauskienė,et al.  [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance]. , 2008, Medicina.

[7]  Emmanuel Roilides,et al.  Differential Correlation Between Rates of Antimicrobial Drug Consumption and Prevalence of Antimicrobial Resistance in a Tertiary Care Hospital in Greece , 2008, Infection Control &#x0026; Hospital Epidemiology.

[8]  I. Gould.  Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. , 2008, International journal of antimicrobial agents.

[9]  Jessina C. McGregor,et al.  Clinical Prediction Tool To Identify Patients with Pseudomonas aeruginosa Respiratory Tract Infections at Greatest Risk for Multidrug Resistance , 2006, Antimicrobial Agents and Chemotherapy.

[10]  Y. Carmeli,et al.  Differential Effects of Levofloxacin and Ciprofloxacin on the Risk for Isolation of Quinolone-Resistant Pseudomonas aeruginosa , 2006, Antimicrobial Agents and Chemotherapy.

[11]  Matthew Bidwell Goetz,et al.  Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. , 2005, Chest.

[12]  S. Zakynthinos,et al.  Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria , 2005, Intensive Care Medicine.

[13]  M. Kollef,et al.  Pseudomonas aeruginosa Bloodstream Infection: Importance of Appropriate Initial Antimicrobial Treatment , 2005, Antimicrobial Agents and Chemotherapy.

[14]  G. Rossolini,et al.  Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[15]  M. Kollef.  Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of the carbapenems. , 2004, Respiratory care.

[16]  D. Livermore,et al.  Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. , 2004, The Journal of antimicrobial chemotherapy.

[17]  Ronald N. Jones,et al.  Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). , 2004, The Journal of antimicrobial chemotherapy.

[18]  J. Quinn,et al.  An update on antibiotic-resistant gram-negative bacteria , 2004 .

[19]  S. Harbarth,et al.  Antibiotic Consumption, Bacterial Resistance and their Correlation in a Swiss University Hospital and its Adult Intensive Care Units , 2003, Scandinavian journal of infectious diseases.

[20]  J. Karlowsky,et al.  Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001 , 2003, Antimicrobial Agents and Chemotherapy.

[21]  J. Eldere.  Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections , 2003 .

[22]  P. Nordmann,et al.  Prospective Survey of β-Lactamases Produced by Ceftazidime- Resistant Pseudomonas aeruginosa Isolated in a French Hospital in 2000 , 2002, Antimicrobial Agents and Chemotherapy.

[23]  O. Cars,et al.  A European study on the relationship between antimicrobial use and antimicrobial resistance. , 2002, Emerging infectious diseases.

[24]  Yves Cohen,et al.  Mortality associated with late-onset pneumonia in the intensive care unit: results of a multi-center cohort study , 2002, Intensive Care Medicine.

[25]  E. Bouza,et al.  Pseudomonas aeruginosa: a Survey of Resistance in 136 Hospitals in Spain , 1999, Antimicrobial Agents and Chemotherapy.

[26]  E. Scott,et al.  Development of resistance and cross‐resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[27]  R. Kozlov,et al.  ANTIMICROBIAL RESISTANCE PATTERNS AMONG AEROBIC GRAM-NEGATIVE BACILLI ISOLATED FROM PATIENTS IN INTENSIVE CARE UNITS: RESULTS OF A MULTICENTER STUDY IN RUSSIA , 1998 .

[28]  G. Bonfiglio,et al.  Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey. , 1998, The Journal of antimicrobial chemotherapy.

[29]  A. Tsakris,et al.  Extended high-level cross-resistance to antipseudomonal antibiotics amongst Pseudomonas aeruginosa isolates in a university hospital. , 1997, The Journal of antimicrobial chemotherapy.

[30]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.